Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Chief Business Officer | March 08, 2019 | March 12, 2019 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, CHIEF FINANCIAL OFFICER | November 18, 2022 | November 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date March 08, 2019 · Filed March 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,639 |
Reported balance
After 2019-03-08 transaction · row 1
1 source rowRow 1 · 2019-03-08 · Grant · Acquired 9,045 · Balance 15,639 F1: Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2019, December 1, 2020, December 1, 2021 and December 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.51 · Expires 2029-03-08 | Direct | 15,075 |
Reported balance
After 2019-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-08 · Grant · Acquired 15,075 · Balance 15,075 F2: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019 with the first quarterly installment vesting on April 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2019, December 1, 2020, December 1, 2021 and December 1, 2022.
F2: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019 with the first quarterly installment vesting on April 1, 2019.
Theravance Biopharma, Inc.
Report date November 18, 2022 · Filed November 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 409,771 |
Reported balance
After 2022-11-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-18 · Sale · Disposed 65,000 · Balance 409,771 F1: This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F2: Includes 1,264 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 384,714 |
Reported balance
After 2022-11-20 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-20 · Tax withholding · Disposed 25,057 · Balance 384,714 F3: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2: Includes 1,264 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022.
F3: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2022 Filed Nov 22, 2022 21:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 25,057 | $10.85 | $271,868.45 |
DisclosureSEC source: 0001415889-22-011671 · form4-11222022_091120.xml · nonDerivative · entry 2 Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,714 F3 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | SaleOrdinary Shares | 65,000 | $11.02 | $716,241.50 |
DisclosureSEC source: 0001415889-22-011671 · form4-11222022_091120.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,771 F1 · price: This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 1,264 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 23:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 25,676 | $9.34 | $239,813.84 |
DisclosureSEC source: 0001415889-22-008983 · form4-08232022_040813.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,507 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:56 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008006 · form4-07272022_030759.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,183 F1 · shares: On July 1, 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On June 30 2022, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on August 20, 2023, subject to the reporting person's continued service. Read SEC document |
| May 20, 2022 Filed May 24, 2022 23:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,365 | $8.74 | $29,410.10 |
DisclosureSEC source: 0001415889-22-005631 · form4-05242022_040517.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,183 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. F2 · balance_after: Includes 1,263 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 13, 2022. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 23:29 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 25,973 | $9.61 | $249,600.53 |
DisclosureSEC source: 0001415889-22-001699 · form4-02232022_030232.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,285 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| December 02, 2021 Filed Dec 7, 2021 00:53 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 340,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-010638 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,258 F1 · shares: On December 2, 2021, the reporting person was granted 340,000 RSUs. 240,000 RSUs are subject to service-based vesting conditions and the remaining 100,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:22 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 1,350 | $8.36 | $11,286.00 |
DisclosureSEC source: 0001415889-21-005466 · form4-11232021_051122.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,258 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. F2 · balance_after: Includes 1228 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2021. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 22:55 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 17,464 | $14.05 | $245,369.20 |
DisclosureSEC source: 0001179110-21-008394 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,380 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2021 Filed May 24, 2021 22:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 942 | $17.80 | $16,767.60 |
DisclosureSEC source: 0001179110-21-005842 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,844 F1 · balance_after: Includes 1,082 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 14, 2021. Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 23:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,984 | $18.79 | $74,859.36 |
DisclosureSEC source: 0001179110-21-002160 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,704 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:43 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001536 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,688 F1 · balance_after: Includes 553 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 13, 2020. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:24 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,323 | $18.22 | $78,765.06 |
DisclosureSEC source: 0001179110-20-009265 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,135 Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008540 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,458 F1 · shares: On July 1 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On July 27, 2020, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on August 20, 2021, subject to the reporting person's continued service. F2 · balance_after: Includes 968 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 00:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,060 | $25.90 | $182,854.00 |
DisclosureSEC source: 0001179110-20-002146 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,490 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 23:58 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001200 · edgar.xml · nonDerivative · entry 2 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,550 F1 · shares: On July 1 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On February 3, 2020, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 23:58 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 43,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001200 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,550 Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 22:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $16.94 | $0.00 |
DisclosureSEC source: 0001179110-19-008497 · edgar.xml · derivative · entry 2 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Ordinary Shares · 260,000 shares Expires 2029-06-30 F1 · derivative.exercise_date: This option may be exercised with respect to the first 25% of the shares subject to this option when optionee completes 12 months of continuous service after the Grant Date. This option may be exercised with respect to an additional 1/48th of the shares subject to this option when optionee completes each month of continuous service thereafter. The option shall be fully vested and exercisable on the 4-year anniversary of the Grant Date provided optionee has remained in continuous service through such date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 22:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008497 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 16:15 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 15,075 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001209191-19-018791 · doc4.xml · derivative · entry 2 Hindman Andrew A. · CIK 0001607965 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,075 Underlying: Common Stock · 15,075 shares Expires 2029-03-08 F2 · derivative.exercise_date: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019 with the first quarterly installment vesting on April 1, 2019. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 16:15 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 9,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-018791 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,639 F1 · shares: Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2019, December 1, 2020, December 1, 2021 and December 1, 2022. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 16:15 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 877 | $13.38 | $11,734.26 |
DisclosureSEC source: 0001209191-19-012966 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,594 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4. Read SEC document |
| December 22, 2018 Filed Dec 27, 2018 08:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064141 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,471 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 08:05 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 753 | $20.56 | $15,478.37 |
DisclosureSEC source: 0001209191-18-061104 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,171 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 16:05 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 879 | $20.28 | $17,826.12 |
DisclosureSEC source: 0001209191-18-057552 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,924 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 16:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-050629 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,803 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| May 25, 2018 Filed May 30, 2018 07:51 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 42,615 | $24.26 | $1,034,006.10 |
DisclosureSEC source: 0001209191-18-034062 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,503 F1 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $24.25 to $24.35 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 13, 2018 Filed May 15, 2018 07:57 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 3,930 | $24.35 | $95,695.50 |
DisclosureSEC source: 0001209191-18-030094 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,118 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were delivered to the issuer by the reporting person from vested restricted stock awards to cover tax liability in connection with vesting of those awards. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 08:29 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 5,742 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013209 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,048 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 07:40 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 817 | $20.54 | $16,784.12 |
DisclosureSEC source: 0001209191-17-063696 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,306 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.20 to $20.85 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2017 Filed May 17, 2017 15:57 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 7,704 | $15.75 | $121,318.74 |
DisclosureSEC source: 0001209191-17-033030 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,123 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $15.60 to $15.90 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:18 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $16.50 | $0.00 |
DisclosureSEC source: 0001209191-17-029654 · doc4.xml · derivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-05-01 F1 · derivative.exercise_date: The shares subject to this option vest over two years from the May 1, 2017 grant date, with the first 25% to vest at the end of six months after the grant date and the remaining 75% to vest in equal quarterly installments over the remainder of such two year period. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:34 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $27.48 | $0.00 |
DisclosureSEC source: 0001209191-17-017596 · doc4.xml · derivative · entry 2 Hindman Andrew A. · CIK 0001607965 · Chief Business Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2027-03-01 F2 · derivative.exercise_date: The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2017 with the first quarterly installment vesting on April 1, 2017. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:34 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-017596 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,827 F1 · shares: Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2017, December 1, 2018, December 1, 2019 and December 1, 2020. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 17:09 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 443 | $20.72 | $9,180.07 |
DisclosureSEC source: 0001209191-16-153403 · doc4.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · Chief Business Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,227 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.35 to $21.15 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.